Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125226711 | 12522671 | 1 | I | 20140314 | 20160606 | 20160701 | 20160701 | EXP | PHHY2016TW090392 | NOVARTIS | 50.03 | YR | M | Y | 0.00000 | 20160701 | MD | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125226711 | 12522671 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 400 OT, UNK | 22068 | CAPSULE | |||||||||
| 125226711 | 12522671 | 2 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 5 MG, UNK | Y | 0 | 5 | MG | |||||||
| 125226711 | 12522671 | 3 | C | CB /01734801/ | 2 | Topical | 5 G, UNK | Y | 0 | 5 | G | OINTMENT |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125226711 | 12522671 | 1 | Chronic myeloid leukaemia |
| 125226711 | 12522671 | 2 | Prophylaxis |
| 125226711 | 12522671 | 3 | Prophylaxis |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125226711 | 12522671 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125226711 | 12522671 | 1 | 20031018 | 0 | ||
| 125226711 | 12522671 | 2 | 20140314 | 20140328 | 0 | |
| 125226711 | 12522671 | 3 | 20140214 | 20140509 | 0 |